- Home
- ASAN vs RARE Comparison
ASAN vs RARE Comparison
Compare ASAN & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASAN
- RARE
- Stock Information
- Founded
- ASAN 2008
- RARE 2010
- Country
- ASAN United States
- RARE United States
- Employees
- ASAN N/A
- RARE N/A
- Industry
- ASAN Retail: Computer Software & Peripheral Equipment
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- ASAN Technology
- RARE Health Care
- Exchange
- ASAN Nasdaq
- RARE Nasdaq
- Market Cap
- ASAN 4.8B
- RARE 3.9B
- IPO Year
- ASAN 2020
- RARE 2014
- Fundamental
- Price
- ASAN $17.33
- RARE $37.94
- Analyst Decision
- ASAN Hold
- RARE Strong Buy
- Analyst Count
- ASAN 19
- RARE 14
- Target Price
- ASAN $18.11
- RARE $93.50
- AVG Volume (30 Days)
- ASAN 2.7M
- RARE 791.0K
- Earning Date
- ASAN 03-10-2025
- RARE 05-01-2025
- Dividend Yield
- ASAN N/A
- RARE N/A
- EPS Growth
- ASAN N/A
- RARE N/A
- EPS
- ASAN N/A
- RARE N/A
- Revenue
- ASAN $706,677,000.00
- RARE $560,230,000.00
- Revenue This Year
- ASAN $13.14
- RARE $18.75
- Revenue Next Year
- ASAN $11.02
- RARE $30.27
- P/E Ratio
- ASAN N/A
- RARE N/A
- Revenue Growth
- ASAN 11.89
- RARE 29.01
- 52 Week Low
- ASAN $11.05
- RARE $37.02
- 52 Week High
- ASAN $27.77
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- ASAN 34.57
- RARE 31.04
- Support Level
- ASAN $16.80
- RARE $39.72
- Resistance Level
- ASAN $19.56
- RARE $41.37
- Average True Range (ATR)
- ASAN 1.18
- RARE 1.69
- MACD
- ASAN -0.37
- RARE -0.46
- Stochastic Oscillator
- ASAN 7.72
- RARE 0.00
About ASAN Asana Inc.
Asana is a provider of collaborative work management software delivered via a cloud-based SaaS model. The firm's solution offers scalable, dynamic tools to improve the efficiency of project and process management across countless use cases, including marketing programs, managing IT approvals, and performance management. Asana's offering supports workflow management across teams, provides real time visibility into projects, and reporting and automation capabilities. The firm generates revenue via software subscriptions on a per seat basis.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.